PharmaPoint: Type 2 Diabetes – Global Drug Forecast and Market Analysis to 2026
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
While the global T2D market is crowded with inexpensive generics and marked by a pipeline filled with me-too drugs, GlobalData expects this market to undergo substantial growth between 2016 and 2026, doubling over the forecast period. The main driver of this enormous expansion will be the dramatic increase in disease prevalence, which is attributable to increased life expectancy and an increasingly sedentary and stressful lifestyle. The second largest driver will be physicians’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.
Despite the large number of marketed therapies, the T2D market is still experiencing large unmet needs and therefore has a significant growth opportunity for new patent-protected products. Metformin (dimethylbiguanide) will remain the first-line therapy overall for T2D due to physicians’ familiarity with it and the availability of long-term data, but the usage of sulfonylureas (SUs), another front-line therapy, continues to be replaced by novel therapies with improved side-effect profiles. The battle for second- or third-line therapy will involve DPP-4Is, GLP-1RAs, SGLT-Is, and other upcoming novel therapies. Of all the currently marketed classes, GLP-1RAs and SGLT-Is will experience the fastest growth due to their beneficial CV effects, weight-loss effects, and increasing ease of use.
Scope
Overview of T2D, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Annualized T2D therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2016 and forecast for ten years to 2026.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the T2D therapeutics market.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
Analysis of the current and future market competition in the global T2D therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
Develop business strategies by understanding the trends shaping and driving the global T2D therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global T2D therapeutics market in future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the global T2D therapeutics market from 2016-2026.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Astellas Pharma
AstraZeneca
Biocon
Boehringer Ingelheim
Bristol-Myers Squibb
Chong Kun Dang
Chugai Pharmaceuticals
Daiichi Sankyo
Diasome
Eli Lilly
GlaxoSmithKline
Intarcia Therapeutics
Ionis Pharmaceuticals
Johnson & Johnson
Kowa Company
LG Life Sciences
Ligand Pharmaceuticals
Merck & Co
Mitsubishi Tanabe
Novartis
Novo Nordisk
OPKO Health
Pfizer
Poxel SA
Roche
Sanofi
SatRx
Shenzhen Chipscreen Biosciences
Taisho Pharmaceuticals
Takeda
Theracos
vTv Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.